Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators are examining the activation of insulin signaling factors in skeletal muscles of human diabetics. The investigators are characterizing the defects in signaling, and are examining the effects of anti-diabetic agents and exercise on signaling to glucose transport biochemical machinery and whole body glucose disposal.
We have provided clear evidence that insulin activation of all three signaling components, Viz., IRS-1-dependent PI 3-Kinase, atypical protein kinase C (aPKC) and PKB/Akt is defective in diabetic muscle. These defects are best seen when insulin activation is conducted at both half-maximal and maximal stimulation. Moreover, whereas previous studies had shown that treatment with metformin (Met) alone improves aPKC activation, or that treatment with thiazolidinedione (TZD) alone produces increases in activation of IRS-1/PI3K and aPKC when evaluated at maximal insulin stimulation, we have recently found that combined treatment with Met plus TZD for 6 weeks provokes marked increases in insulin effects on all three signaling factors at both half-maximal and maximal insulin stimulation. This work is being prepared for submission for publication.
We have also evaluated the improvement in insulin signaling in diabetic muscle 4 hours after acute endurance (one-legged) exercise and found that the responsiveness of aPKC to the lipid PI3K-derived activator, PIP3, was improved. Also increased was the activation by insulin of IRS-2-dependent PI3K, ERK1/2, and downstream protein synthesis machinery, viz., p70S6 kinase and eukaryotic elongation factor eEF2. These effects of exercise would be expected to enhance glucose transport and utilization by muscle, and promote protein synthesis, i.e., an anabolic response.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | type 2 diabetic individuals | ||
| Group 2 | type 1 diabetic individuals or those with diabetes secondary to pancreatic disease | ||
| Group 3 | non-diabetic individuals who are not considered to be overweight | ||
| Group 4 | non-diabetic individuals who are considered to be overweight | ||
| Group 5 | non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study | ||
| Group 6 | individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome | ||
| Group 7 | healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles | All muscle samples obtained by 9/30/07, final date for examination of samples 9/30/08 Muscle dependent ability to diminish blood glucose levels during insulin treatment. | PKC-zeta mRNA levels and aPKC activity in muscle evaluated 40 minutes post-insulin treatment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
type 2 diabetes controlled by diet or oral agents and comparable non-diabetic control subjects
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert V Farese, MD | VA Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VA Medical Center | Tampa | Florida | 33612 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18972094 | Result | Temofonte N, Sajan MP, Nimal S, Pastoor T, Fumero C, Casaubon L, Powe JL, Standaert ML, Farese RV. Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Diabetologia. 2009 Jan;52(1):60-4. doi: 10.1007/s00125-008-1180-z. Epub 2008 Oct 30. | |
| 18370676 |
Not provided
Not provided
Individual participant data will not be shared, as data is presented in the published paper as a mean plus or minus SEM.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Group 1 | Type 2 diabetic |
| FG001 | Group 2 | Type 1 diabetic |
| FG002 | Group 3 | Control (non-diabetic) |
| FG003 | Group 4 | Non-diabetic overweight |
| FG004 | Group 5 | Non-diabetic and Type 2 diabetic |
| FG005 | Group 6 | Impaired glucose tolerance (IGT) |
| FG006 | Group 7 | Non-diabetic treated with Metformin |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Group 1 | Type 2 diabetic |
| BG001 | Group 2 | Type 1 Diabetic |
| BG002 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles | All muscle samples obtained by 9/30/07, final date for examination of samples 9/30/08 Muscle dependent ability to diminish blood glucose levels during insulin treatment. | PKC-zeta mRNA and aPKC activity in vastus lateralis skeletal muscle was measured by analysis of gene expression levels of PKC and measuring them in relative amounts in comparison to control subjects. | Posted | Mean | Standard Error | arbitrary units/ng rRNA | PKC-zeta mRNA levels and aPKC activity in muscle evaluated 40 minutes post-insulin treatment |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Group 1 | Diabetics |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Syncopal event | General disorders | Non-systematic Assessment |
As the study progressed, it was determined that there was not scientific merit to the Groups 2, 5 or 7. These groups were, therefore, not pursued.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Robert Farese, MD | James A. Haley VA Research Department | 813-972-2000 | Robert.Farese@va.gov |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Muscle biopsies taken before and after insulin stimulation in euglycemic clamp studies
| Result |
| Beeson M, Sajan MP, Daspet JG, Luna V, Dizon M, Grebenev D, Powe JL, Lucidi S, Miura A, Kanoh Y, Bandyopadhyay G, Standaert ML, Yeko TR, Farese RV. Defective Activation of Protein Kinase C-z in Muscle by Insulin and Phosphatidylinositol-3,4,5,-(PO(4))(3) in Obesity and Polycystic Ovary Syndrome. Metab Syndr Relat Disord. 2004 Spring;2(1):49-56. doi: 10.1089/met.2004.2.49. |
| 17028898 | Result | Casaubon L, Sajan MP, Rivas J, Powe JL, Standaert ML, Farese RV. Contrasting insulin dose-dependent defects in activation of atypical protein kinase C and protein kinase B/Akt in muscles of obese diabetic humans. Diabetologia. 2006 Dec;49(12):3000-8. doi: 10.1007/s00125-006-0471-5. Epub 2006 Oct 7. |
| 16395615 | Result | Luna V, Casauban L, Sajan MP, Gomez-Daspet J, Powe JL, Miura A, Rivas J, Standaert ML, Farese RV. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects. Diabetologia. 2006 Feb;49(2):375-82. doi: 10.1007/s00125-005-0112-4. Epub 2006 Jan 5. |
| 12882907 | Result | Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003 Aug;52(8):1926-34. doi: 10.2337/diabetes.52.8.1926. |
| Group 3 |
Control (non-diabetic) |
| BG003 | Group 4 | Non-Diabetic Overweight |
| BG004 | Group 5 | Non-Diabetic and Type 2 Diabetic subjected to exercise study |
| BG005 | Group 6 | Impaired glucose tolerance (IGT) |
| BG006 | Group 7 | Non-Diabetic treated with Metformin |
| BG007 | Total | Total of all reporting groups |
| years |
|
| Gender | Number | participants |
|
| Region of Enrollment | Number | participants |
|
Type 1 diabetic
| OG002 | Group 3 | Control (non-diabetic) |
| OG003 | Group 4 | Non-diabetic overweight |
| OG004 | Group 5 | Non-diabetic and Type 2 diabetic |
| OG005 | Group 6 | Impaired glucose tolerance (IGT) |
| OG006 | Group 7 | Non-diabetic treated with Metformin |
|
|
|
| 0 |
| 30 |
| 2 |
| 30 |
| EG001 | Group 2 | Type 1 diabetes | 0 | 0 | 0 | 0 |
| EG002 | Group 3 | Control (non-diabetic) | 0 | 97 | 0 | 51 |
| EG003 | Group 4 | Non-diabetic overweight | 0 | 20 | 0 | 15 |
| EG004 | Group 5 | Non-diabetic and Type 2 diabetic | 0 | 0 | 0 | 0 |
| EG005 | Group 6 | Impaired glucose tolerance (IGT) | 0 | 10 | 0 | 6 |
| EG006 | Group 7 | Non-diabetic treated with Metformin | 0 | 0 | 0 | 0 |
| Chest pain | Cardiac disorders | Non-systematic Assessment |
|
Not provided
Not provided
| D004700 | Endocrine System Diseases |